JP2013525473A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525473A5
JP2013525473A5 JP2013508559A JP2013508559A JP2013525473A5 JP 2013525473 A5 JP2013525473 A5 JP 2013525473A5 JP 2013508559 A JP2013508559 A JP 2013508559A JP 2013508559 A JP2013508559 A JP 2013508559A JP 2013525473 A5 JP2013525473 A5 JP 2013525473A5
Authority
JP
Japan
Prior art keywords
group
ortho
meta
optionally substituted
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013508559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525473A (ja
JP5812541B2 (ja
Filing date
Publication date
Priority claimed from HU1000243A external-priority patent/HUP1000243A2/hu
Application filed filed Critical
Publication of JP2013525473A publication Critical patent/JP2013525473A/ja
Publication of JP2013525473A5 publication Critical patent/JP2013525473A5/ja
Application granted granted Critical
Publication of JP5812541B2 publication Critical patent/JP5812541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013508559A 2010-05-06 2011-05-06 8−ヒドロキシキノリン誘導体 Active JP5812541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
HUP1000243 2010-05-06
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (3)

Publication Number Publication Date
JP2013525473A JP2013525473A (ja) 2013-06-20
JP2013525473A5 true JP2013525473A5 (enExample) 2014-06-26
JP5812541B2 JP5812541B2 (ja) 2015-11-17

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508559A Active JP5812541B2 (ja) 2010-05-06 2011-05-06 8−ヒドロキシキノリン誘導体

Country Status (21)

Country Link
US (1) US8871937B2 (enExample)
EP (1) EP2566849B1 (enExample)
JP (1) JP5812541B2 (enExample)
KR (1) KR101837974B1 (enExample)
CN (1) CN102985407B (enExample)
AU (1) AU2011256989B2 (enExample)
CA (1) CA2798419C (enExample)
CY (1) CY1122426T1 (enExample)
DK (1) DK2566849T3 (enExample)
EA (1) EA021026B1 (enExample)
ES (1) ES2761832T3 (enExample)
HR (1) HRP20192278T1 (enExample)
HU (2) HUP1000243A2 (enExample)
MX (1) MX337999B (enExample)
NZ (1) NZ603967A (enExample)
PL (1) PL2566849T3 (enExample)
PT (1) PT2566849T (enExample)
RS (1) RS59678B1 (enExample)
SI (1) SI2566849T1 (enExample)
SM (1) SMT201900710T1 (enExample)
WO (1) WO2011148208A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
US10624881B2 (en) * 2015-10-12 2020-04-21 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟(胺)基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544972B1 (en) 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AU2474399A (en) 1998-01-26 1999-08-09 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
IL148426A0 (en) 1999-08-27 2002-09-12 Cytovia Inc α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
AU2002213174A1 (en) 2000-10-13 2002-04-22 Massaharu Akao Treatment of apoptotic cell death
US6552076B2 (en) 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
DE60233738D1 (de) 2001-07-10 2009-10-29 Biogen Idec Inc Hemmung des apoptoseprozesses und verbesserung der zelleistung
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
US7364757B2 (en) 2002-02-13 2008-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating vascular disease
KR20050118169A (ko) 2003-02-28 2005-12-15 이노텍 파마슈티컬스 코포레이션 사환식 벤즈아미드 유도체 및 이것의 사용 방법
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004105700A2 (en) 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2007059230A2 (en) 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP3085367A3 (en) * 2007-03-20 2017-01-25 Brandeis University Compositions for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
US20080293699A1 (en) 2007-05-25 2008-11-27 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
WO2009151972A1 (en) * 2008-05-28 2009-12-17 , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
EP2521553A4 (en) * 2010-01-06 2013-08-28 Errico Joseph P METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS

Similar Documents

Publication Publication Date Title
JP2020530487A5 (enExample)
JP2019518766A5 (enExample)
JP2010520264A5 (enExample)
RU2013147400A (ru) Способ получения производных кето-бензофурана
JP2016505614A5 (enExample)
JP2017508733A5 (enExample)
JP2017527561A5 (enExample)
JP2015509535A5 (enExample)
JP2015508092A5 (enExample)
JP2009263394A5 (enExample)
JP2016121196A5 (enExample)
JP2014521625A5 (enExample)
JP2010520265A5 (enExample)
JP2016535732A5 (enExample)
JP2017504635A5 (enExample)
JP2013544860A5 (enExample)
JP2017533237A5 (enExample)
JP2016507581A5 (enExample)
JP2011517443A5 (enExample)
JP2017519754A5 (enExample)
SI3102573T1 (en) SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7
JP2009538910A5 (enExample)
IL278579B2 (en) Heteroaryl compounds and uses thereof
JP2013511511A5 (enExample)
JP2016529315A5 (enExample)